SecuraBio

• A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

  Phase 3, Recruiting, 124 people, Jul 26, 2024

• NCT05065866

  Collaborator, Phase 1, Completed, 14 people, Oct 4, 2021

• NCT05057247

  Collaborator, Phase 2, Completed, 26 people, Sep 27, 2021

• NCT05044039

  Collaborator, Phase 1, Active, not recruiting, 42 people, Sep 14, 2021

• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

  Phase 1/2, Terminated, 2 people, Dec 10, 2019

• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

  Collaborator, Phase 1/2, Completed, 55 people, May 23, 2018

• NCT03256045

  Collaborator, Phase 2, Terminated, 9 people, Aug 21, 2017

• Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

  Phase 2, Withdrawn, 0 people, Nov 16, 2015

• A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

  Phase 3, Withdrawn, 0 people, Oct 15, 2015

• A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

  Phase 1/2, Terminated, 55 people, Mar 18, 2015

• Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

  Phase 3, Terminated, 13 people, Jul 31, 2014

• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

  Collaborator, Phase 1/2, Active, not recruiting, 32 people, Jun 6, 2014

• Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

  Phase 1, Completed, 14 people, Sep 20, 2013

• Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

  Phase 1, Completed, 14 people, Aug 20, 2013

Sources: clinicaltrials.gov

• Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma

  Consulting or advice, Dec 2, 2024

• Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia

  Consulting or advice, Fees or honoraria, Nov 24, 2023

Sources: pubmed.ncbi.nlm.nih.gov